Waltermire Robert E. 4
4 · MADRIGAL PHARMACEUTICALS, INC. · Filed Jun 18, 2024
Insider Transaction Report
Form 4
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Transactions
- Exercise/Conversion
Common Stock
2024-06-14$87.09/sh+1,900$165,471→ 7,400 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-06-14−1,900→ 10,350 totalExercise: $87.09Exp: 2032-02-24→ Common Stock - Sale
Common Stock
2024-06-14$280.00/sh−1,900$532,000→ 5,500 total
Footnotes (1)
- [F1]All shares issued pursuant to the exercise of the options reported herein represent 1,900 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.